A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms OPUS
  • Sponsors Biogen
  • Most Recent Events

    • 24 Oct 2017 Status changed from not yet recruiting to recruiting in Oct 2017, according to a Biogen media release.
    • 18 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top